Q3:2025 Business Update and Financial Results October 29, 2025 Nasdaq: IONS 1 On Today's Earnings Call Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research 2 Richard Geary, Ph.D. Chief Development Officer Kyle Jenne Chief Global Product Strategy Officer Beth Hougen Chief Financial Officer Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial pote ...

2 Ionis Leadership Here Today Innovation Day 2025: Accelerating Growth through Life-Changing Medicines OCTOBER 7, 2025 | Nasdaq: IONS Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, fina ...

Group 1 - Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is considered one of the best stocks to buy for the next three months according to hedge funds, with a Buy rating and a price target of $80 set by H.C. Wainwright analyst Patrick Trucchio [1] - The recent deal with Novartis is highlighted as a strong vote of confidence, providing $200 million upfront and the potential for a $2 billion milestone, which validates Arrowhead's approach to treating CNS diseases and adds funding without share dilution [2] - Positive results from Ionis Pharmaceuticals' Olezarsen support Arrowhead's Plozasiran drug, both targeting severe hypertriglyceridemia, with Arrowhead's offering of quarterly dosing potentially attracting more patients and doctors [3]

Q2:2025 Business Update and Financial Results July 30, 2025 Nasdaq: IONS 1 On Today's Earnings Call Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research 2 Brett Monia, Ph.D. Chief Executive Officer Kyle Jenne Chief Global Product Strategy Officer In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a registered trademark ...